Avanos Medical (AVNS) last issued guidance on February 24, 2026 for fiscal year 2026. The company guided earnings per share in the range of $0.90 - $1.10, compared to a consensus EPS estimate of $1.03. Avanos Medical also guided revenue in the range of $700.00M - $720.00M for the period.
Compared to prior guidance, Avanos Medical raised its revenue forecast from a prior range of $690.00M - $700.00M.
Avanos Medical has issued 22 guidance updates between May 4, 2022 and February 24, 2026. During this period, the company raised its outlook 5 times and lowered it 9 times, providing investors with insight into management's evolving expectations.
Review all historical guidance issued by Avanos Medical, including EPS and revenue forecasts across quarterly and annual periods.
The most recent guidance for Avanos Medical (AVNS) was reported on February 24, 2026 for the fiscal year 2026. The company provided earnings per share guidance in the range of $0.90 to $1.10, compared to the estimated EPS of $1.03. Additionally, Avanos Medical forecasted revenue between $700.00M and $720.00M for the period.
Avanos Medical (AVNS) guided EPS in the range of $0.90 to $1.10 for the fiscal year 2026. The consensus analyst EPS estimate is $1.03.
Avanos Medical (AVNS) guided revenue in the range of $700.00M to $720.00M for the fiscal year 2026.
Avanos Medical (AVNS) raised its revenue guidance from a prior range of $690.00M - $700.00M to $700.00M - $720.00M for the fiscal year 2026.
Avanos Medical (AVNS) last issued guidance on February 24, 2026 for the fiscal year 2026.